|Bid||0.0000 x 1800|
|Ask||0.0000 x 1300|
|Day's Range||1.6200 - 1.6400|
|52 Week Range||0.7000 - 1.8900|
|Beta (5Y Monthly)||1.34|
|PE Ratio (TTM)||N/A|
|Earnings Date||Sep 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company, has qualified to trade on the OTCQX® Best Market. Emmaus Life Sciences, Inc. upgraded to OTCQX from the Pink® market.
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Emmaus Life Sciences The Trade: Emmaus Life Sciences, Inc. (OTC: EMMA) Chairman and CEO Yutaka Niihara acquired a total of
Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced financial results for the six months ended June 30, 2021. As a result, the company is now current in its Securities and Exchange Commission (SEC) reporting obligations.